Atriva Therapeutics GmbH
“Atriva Therapeutics is a clinical stage biopharmaceutical company developing host-targeting inhibitors against severe respiratory viral infections.”
Atriva Therapeutics is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies against different severe respiratory viral infections. The Company, located in Tübingen and Frankfurt, Germany, was founded in 2015 by a team of leading scientists in viral research and seasoned industry experts. Atriva’s lead drug candidate ATR-002 is a host-targeting MEK inhibitor, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development and has successfully proven safety and tolerability in healthy subjects in a Phase I trial. The Company owns nine patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies.
New antiviral mode of action with high resistance barrier and broad activity.
Over EUR 700 Mn projected retail peak sales of ATRIVA’s MEK inhibitors in Influenza to be reached five years after first launch.
ATR-002 has successfully proven safety and tolerability in healthy subjects in a Phase I trial.
- Atriva mit überzeichneter Wandelanleihe in Höhe von 8,6 Mio. EUR
- Vier Wochen bis zum fertigen Impfstoff
- Atriva Therapeutics gibt ersten Abschluss der Serie A-Finanzierung bekannt
- Atriva Therapeutics: Zweite Tranche der Seed-Finanzierung von insgesamt drei Mio. EUR
- Gegen Grippe: Atriva erhält Seedfinanzierung